Me: SP could go over $4 with COVID indication appr

Me: SP could go over $4 with COVID indication approval

You: “However, if you are saying post-FDA approval we'll see the SP over $4 -- then I would have to respectfully disagree.”

If leronlimab receives COVID approval, I anticipate $6-12 based on irrational exuberance alone.”

I graduated long before “core curriculum” became the standard, but I’m pretty sure my estimate of an SP over $4 upon FDA approval includes $6-12. I was using $4 as a pivot point for uploading

Now, I don’t play the SP guessing game, but $6-12 seems a little steep for just the COVID indication, especially considering manufacturing restrictions and timing of FDA approval (next week? next month? August?). But then again, rationale doesn’t always drive smart investing decisions when the FDA emergency approves a drug for COVID. I can see an SP rise from people buying the hype and me taking some nice profits at the top.

My hope is the CYDY makes some enough profits from COVID19 to fund the mono therapy trial, GvHD trial, and other cancer trials without the need for more financing. Heck, if they make enough to go the cancer indication alone, I’d be happy with that too.